Drug Channels

JANUARY 28, 2022

Fiza discusses the impending influx of biosimilars and its effect on manufacturers, specifically in the immunology space. To learn more, sign up for MMIT’s Immunology Biosimilars webcast. It's a moderated discussion with payers on how the changing market might impact their management strategies in immunology.

Biosimilars 98

Biosimilars Marketing Drugs 98

ProRelix Research

JULY 6, 2023

Biosimilar clinical trials and study designs’ Considerations The rising prevalence and large market share of biological products emphasize their importance as treatment options for several cancers and autoimmune diseases.

Clinical Trials 105

Clinical Trials Biosimilars Trials Treatment 105

Drug Patent Watch

DECEMBER 10, 2024

Biosimilars have been transforming the pharmaceutical landscape by offering cost-effective alternatives to biologic drugs. As patents for these biologics expire, the market for biosimilars is expanding rapidly, with significant implications for manufacturing technologies.

Biosimilars 97

Biosimilars Drugs Production Clinical Trials 97

Drug Channels

OCTOBER 3, 2023

Since I published the article below in July 2023 , there have been three notable market develpoments: IQVIA has reported that as as of mid-2023, there was almost no adoption of Amgen's Amjevita, the first Humira biosimilar. Boehringer-Ingelheim launched an unbranded, low WAC version of its interchangeable biosimilar.

Biosimilars 98

Biosimilars Pharmacy Marketing Pharmaceuticals 98

Drug Channels

JULY 18, 2023

The Humira biosimilar market has arrived! This month, nine biosimilar versions of adalimumab launched in the U.S. Surprisingly, two PBMs—Express Scripts and OptumRx—will each offer at least one low-list-price biosimilar option on their main national formularies.

Biosimilars 98

Biosimilars Pharmacy Marketing Drugs 98

Drug Channels

SEPTEMBER 7, 2022

As regular readers know, the biosimilar boom for provider-administered drugs has been accelerating. In many therapeutic areas, biosimilars’ market share is approaching 80%. will face multiple biosimilar competitors. Prices are dropping while adoption accelerates. I also offer some thoughts on 2023 and 2024.

Biosimilars 98

Biosimilars Marketing Drugs Production 98

Drug Patent Watch

NOVEMBER 20, 2024

The pharmaceutical industry is constantly evolving, and one of the most exciting areas of growth is the development of biosimilars. However, the journey from concept to market is fraught with challenges. Let’s dive into the intricate world of… Source

Biosimilars 98

Biosimilars Pharmaceuticals Treatment Production 98

Drug Patent Watch

DECEMBER 8, 2024

The pharmaceutical industry is heavily reliant on patents to protect intellectual property and maintain market exclusivity. However, with the increasing competition from generic and biosimilar manufacturers, patent invalidity claims have become a significant challenge for pharmaceutical companies.

Biosimilars 98

Biosimilars Pharmaceutical Companies Drugs Pharmaceuticals 98

Drug Patent Watch

DECEMBER 12, 2024

This approach not only helps maintain market exclusivity but also ensures a steady revenue stream for pharmaceutical companies. Understanding the Pharmaceutical Market Dynamics The pharmaceutical industry is a complex ecosystem where branded drugs and generics coexist, each playing a vital role in patient care and market dynamics.

Licensing 96

Licensing Licensing Drugs Clinical Trials 96

Drug Patent Watch

FEBRUARY 3, 2021

Abstract Biosimilar medicines expand the biotherapeutic market and improve…. The post The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA appeared first on DrugPatentWatch - Make Better Decisions.

Biosimilars 98

Biosimilars FDA Licensing Licensing 98

Drug Channels

FEBRUARY 7, 2023

As you've surely heard, Amgen has just launched Amjevita, the first non-interchangeable biosimilar of Humira. Its strategy echoes the pricing of the first interchangeable insulin biosimilars— as I predicted in 2021. Unfortunately, we should expect most PBMs and plan sponsors to embrace the high-list/high-rebate version.

Biosimilars 98

Biosimilars Drugs Production Marketing 98

Drug Channels

OCTOBER 14, 2022

Today’s guest post comes from Steve Callahan, Senior Manager of Market Research at MMIT. Steve walks us through the expected Humira biosimilars launches and discusses potential responses from payers. To learn more, check out MMIT’s Strategic Launch Report & Evaluate Forecast solution. Read on for Steve’s insights.

Biosimilars 98

Biosimilars Pharma Companies Marketing Drugs 98

BioPharma Drive: Drug Pricing

FEBRUARY 26, 2024

The companies didn’t reveal their planned price for Simlandi, which will be the 10th Humira copycat to reach the U.S.

FDA Approval 157

FDA Approval Biosimilars FDA Marketing 157

Drug Channels

OCTOBER 6, 2020

The biosimilar market is finally beginning to fulfill its promise. The latest data show that provider-administered biosimilar drugs are successfully displacing their reference biological products. As I predicted last year, newer biosimilars are being adopted quickly, and their prices are declining rapidly.

Biosimilars 52

Biosimilars Marketing Regulations FDA 52

Drug Channels

SEPTEMBER 13, 2022

These include disruption to the now-booming biosimilar market, the prospects of physician/hospital vertical integration that will raise commercial healthcare costs and expand 340B, and the need for complex new processes to administer the IRA's lower pharmacy reimbursements.

Biosimilars 97

Biosimilars Pharmacy Hospitals Marketing 97

Drug Channels

DECEMBER 17, 2020

Conveniently for HHS, ASPE's analysis stopped before the biosimilar boom began. The biosimilar market is finally beginning to fulfill its promise. The latest data show that provider-administered biosimilar drugs are successfully displacing their reference biological products. d/b/a Drug Channels Institute.

Biosimilars 52

Biosimilars Marketing Regulations FDA 52

BioPharma Drive: Drug Pricing

OCTOBER 15, 2024

Biosimilar competition is expected in early January for the company’s second highest-selling drug, putting greater focus on newer products' market trajectory.

Biosimilars 135

Biosimilars Production Marketing Drugs 135

Drug Channels

DECEMBER 12, 2022

These include disruption to the now-booming biosimilar market, the prospects of physician/hospital vertical integration that will raise commercial healthcare costs and expand 340B, and the need for complex new processes to administer the IRA's lower pharmacy reimbursements.

Biosimilars 98

Biosimilars Pharmacy Hospitals Marketing 98

Drug Channels

DECEMBER 11, 2023

One update: CVS Caremark's 2024 formulary for patient-administered autoimmune products prefers: Humira Hyrimoz (the high WAC Sandoz biosimilar) adalimumab-adaz (the unbranded, low WAC Sandoz biosimilar) Perhaps coincidentally, Sandoz products are marketed by Cordavis, the new business described in today's rerun.

Biosimilars 75

Biosimilars Pharmacy Production Marketing 75

Drug Channels

JULY 20, 2022

In this issue: CVS disassociates itself from its chain pharmacy association Payers are paying attention to ICER Benefits of the biosimilar boom A fantastic takedown of health insurance deductibles Plus, I join the Advisory Board of Alto Pharmacy. Cut through the steamy summer haze with our refreshing selection of articles and insights.

Biosimilars 98

Biosimilars Pharmacy Drugs Marketing 98

Drug Channels

SEPTEMBER 6, 2023

CVS Health has finally revealed its strategy for biosimilars of AbbVie’s Humira. Rather than announce multiple biosimilars for its pharmacy benefit manager (PBM) formulary, the company will instead launch Cordavis, a new subsidiary that will market a private label, low-list-price version of Sandoz’ Hyrimoz.

Biosimilars 75

Biosimilars Pharmacy Drugs Marketing 75

Drug Channels

SEPTEMBER 8, 2021

Fein, CEO of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for his latest video webinar: Drug Channels Update: Buy-and-Bill Market Trends. Friday, September 24, 2021, from 12:00 p.m. to 1:30 p.m. ET This page describes the event and explains how to purchase a registration.

Marketing 97

Marketing Biosimilars Drugs Hospitals 97

BioPharma Drive: Drug Pricing

JULY 26, 2023

In challenging AbbVie for share of a $19 billion drug market, competitors are testing whether high upfront discounts or behind-the-scenes rebates can win them an advantage.

Biosimilars 130

Biosimilars Marketing Drugs 130

Drug Channels

MARCH 30, 2023

So far, it appears that PBMs are neither preferring Amgen's Humira biosimilar nor embracing the low-list/low-rebate version. As you've surely heard, Amgen has just launched Amjevita, the first non-interchangeable biosimilar of Humira. In February, AbbVie stated that U.S.

Biosimilars 75

Biosimilars Pharmacy Drugs Production 75

Drug Patent Watch

JUNE 17, 2024

The article “The devil is in the divisional: an analysis of divisional patents, deadlines, declarations and suggestions for future practice” by Mieke Filler provides a comprehensive analysis of the strategic use of divisional patents in the pharmaceutical sector to delay generic and biosimilar market entry.

Biosimilars 110

Biosimilars Pharmaceuticals Marketing 110

The Pharma Data

JUNE 30, 2021

Agreement includes commercializing biosimilar candidate of ophthalmology drug ranibizumab (Lucentis ® ) in Europe, Canada, Israel and global markets. Bioeq has in-licensed the exclusive global commercialization rights to FYB201 from the German biosimilar developer Formycon AG.

Biosimilars 52

Biosimilars International Licensing Licensing 52

FDA Law Blog: Biosimilars

APRIL 2, 2024

Under the heading “Facilitating Competition” are multiple initiatives designed to either hasten development of generic drugs or limit blockades to market. In the second category—limiting blockades to marketing—are efforts to limit blocking exclusivities and induced infringement liability.

FDA 104

FDA Biosimilars Production Marketing 104

Drug Channels

SEPTEMBER 4, 2024

The Humira biosimilar market just took another step forward—but remains far from its ideal state. Last week, Cigna’s Express Scripts announced that it that will follow CVS Health’s CVS Caremark business and remove Humira from its largest commercial formulary in favor of multiple biosimilars.

Biosimilars 52

Biosimilars Production Marketing Drugs 52

Drug Channels

AUGUST 16, 2024

Today’s guest post comes from Benjamin Hinton II, Senior Market Access Solutions Analyst at MMIT. Benjamin reviews the growing trend of PBMs vertically integrating into the production of biosimilars. The findings shed light on payers' view of biosimilar conpetition, contracting challenges, and other issues.

Biosimilars 78

Biosimilars Marketing Production Research 78

The Pharma Data

JULY 29, 2021

Food and Drug Administration approved the first interchangeable biosimilar insulin product, indicated to improve glycemic control in adults and pediatric patients with Type 1 diabetes mellitus and in adults with Type 2 diabetes mellitus. Semglee (insulin glargine-yfgn) is the first interchangeable biosimilar product approved in the U.S.

Biosimilars 52

Biosimilars Production FDA Approval FDA 52

The Pharma Data

JUNE 17, 2022

Submission supported by comprehensive analytical and clinical data from new Phase I bridging pharmacokinetics study Adalimumab’s high-concentration 100 mg/mL formulation aims to provide an enhanced yet familiar experience for patients Submission builds on Sandoz’ well established biosimilar immunology portfolio in Europe.

Biosimilars 52

Biosimilars Pharmacokinetics FDA Approval Packaging 52

Drug Channels

APRIL 3, 2024

The 2024 formularies described below should boost biosimilar adoption. As a new Biosimilar Council report shows , Humira retained 99% of market share in late 2023, despite being more expensive than its biosimilars. This year, Humira and its 14 biosimilars will provide the most intriguing formulary drama.

Biosimilars 52

Biosimilars Pharmacy Drugs Production 52

The Pharma Data

MAY 8, 2021

Sandoz, a Novartis division, today announced progress in the late-stage clinical development program for its proposed biosimilar aflibercept. The initiation of this study marks an important milestone in the development of our biosimilar aflibercept.

Biosimilars 52

Biosimilars Clinical Development Production Government 52

Drug Channels

JANUARY 27, 2023

Saket discusses market access and contracting strategies for medical benefit products when pharmacy benefit biosimilar therapies launch. Today’s guest post comes from Saket Patel, Consultant, Advisory Services at MMIT. He then describes how to automate formulary and medical policies to protect manufacturers from overpayment.

Biosimilars 97

Biosimilars Pharmacy Therapies Production 97

The Pharma Data

APRIL 9, 2021

Biogen enters into a commercialization and license agreement to develop, manufacture and commercialize BAT1806, a proposed biosimilar referencing ACTEMRA ® (tocilizumab). Biosimilars have the potential to enable greater access to marketed biologic therapies while generating cost savings and healthcare sustainability.

Biosimilars 52

Biosimilars Licensing Licensing Therapies 52

Drug Patent Watch

JUNE 3, 2021

Get Your Certificate Today By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stay…. Want insights into the biggest revenue-changing events? ?

Biosimilars 85

Biosimilars Drugs Marketing 85

FDA Law Blog: Biosimilars

JANUARY 11, 2024

The FIE determination released in fall 2023 involves the Reference Product AbbVie’s Humira (adalimumab) and two interchangeable biosimilars—first approved is Cyltezo (adalimumab-adbm), filed by Boehringer Ingelheim Pharmaceuticals, Inc, which was followed by Abrilada (adalimumab-afzb), filed by Pfizer.

Biosimilars 59

Biosimilars FDA Production Marketing 59